

Eprontia - (25 mg/mL; Oral Solution)

| | | | |
|------------------------------|---|-----------------------------|---------------------|
| Generic Name | Topiramate | Innovator | Cutis (Azurity) |
| Dosage | 25 mg/mL; Oral Solution | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | None | Tentative Approvals | None |
| Final Approvals | Less Than 5 | Generic Launches | None |
| Indication | EPRONTIA is indicated for: 1) Epilepsy: Initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older ; adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with LennoxGastaut syndrome in patients 2 years of age and older. 2) Preventive treatment of migraine in patients 12 years of age and older. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.